- This patient's symptoms are most likely due to which of the following changes in her adrenergic receptors during long-term therapy?
Answer: Receptor upregulation
Chronic blockade of receptors with an antagonist can lead to a compensatory increase in the number of receptors on the cell surface, a phenomenon known as upregulation. When the antagonist (propranolol) is abruptly withdrawn, the now-increased number of β-adrenergic receptors are exposed to endogenous catecholamines (epinephrine, norepinephrine), leading to an exaggerated or supersensitive response. This results in symptoms of sympathetic overactivity, such as tachycardia, palpitations, and anxiety.
- Based on this information, which of the following statements correctly compares the pharmacodynamic properties of Drug B to Drug A?
Answer: Drug B has lower potency but higher efficacy.
Efficacy refers to the maximum effect a drug can produce, regardless of the dose. Drug B produces a greater maximal diuresis (4 L) than Drug A (2 L), so it has higher efficacy. Potency refers to the amount of drug needed to produce a given effect (often measured by ED50). Drug B requires a higher dose (40 mg) to achieve 50% of its maximal effect compared to Drug A (20 mg), indicating it has lower potency. Therefore, Drug B has lower potency but higher efficacy than Drug A.
- The receptor for hydrocortisone is located in which of the following cellular compartments?
Answer: Cytoplasm
Steroid hormones, such as glucocorticoids (e.g., hydrocortisone), are lipophilic molecules that can easily cross the cell membrane. Their receptors are intracellular, located primarily in the cytoplasm. Upon binding the hormone, the receptor-hormone complex undergoes a conformational change, translocates to the nucleus, and acts as a transcription factor by binding to specific DNA sequences (glucocorticoid response elements) to modify gene expression.
- The precipitation of withdrawal symptoms in this patient is best explained by nalbuphine acting as what at the μ-opioid receptor?
Answer: A partial agonist/mixed agonist-antagonist
Nalbuphine is a mixed agonist-antagonist opioid. It is an antagonist at μ-receptors and an agonist at κ-receptors. When given to a patient who is physically dependent on a full μ-agonist like morphine, nalbuphine competitively displaces morphine from the μ-receptors. Because nalbuphine has no agonist activity (or much lower intrinsic activity) at the μ-receptor, this displacement causes a rapid decrease in receptor stimulation, precipitating an acute withdrawal syndrome. This demonstrates that a partial agonist or antagonist can reverse the effects of a full agonist.
- How does the presence of metoprolol alter the dose-response curve for epinephrine at β-adrenergic receptors?
Answer: Shifts the curve to the right, with no change in maximal effect.
Metoprolol is a competitive antagonist. Competitive antagonists bind reversibly to the same site as the agonist (epinephrine). This increases the concentration of agonist required to produce a given effect, shifting the dose-response curve to the right (decreasing potency). However, because the binding is reversible, the antagonism can be overcome by adding more agonist. Therefore, the maximal effect (efficacy) is not changed. A noncompetitive antagonist would decrease the maximal effect.
- The presence of which of the following best explains this observation?
Answer: Spare receptors
This phenomenon describes the concept of spare receptors. A system has spare receptors when a maximal pharmacologic response can be elicited by an agonist at a concentration that does not occupy all available receptors. This indicates a high degree of coupling between receptor activation and downstream signaling pathways. This is common for hormones like insulin and for catecholamines acting on β-adrenergic receptors. Partial agonism would result in a submaximal response. Downregulation is a decrease in receptor number over time. Competitive antagonism would inhibit the response.
- Which of the following statements best describes the pharmacodynamic properties of Drug X compared to Drug Y?
Answer: Drug X has greater potency.
Potency refers to the concentration or dose of a drug required to produce 50% of its maximal effect. Since Drug X has a lower ED50 (10 mg) compared to Drug Y (50 mg), it is more potent. Efficacy is the maximal effect a drug can produce. The passage states that both drugs produce the same maximal effect, so their efficacies are equal. There is not enough information to determine if Drug X is a partial agonist or to compare their therapeutic indices.
- Which of the following pharmacodynamic changes is the most likely cause of the decreased effectiveness of albuterol in this patient?
Answer: Downregulation of β2-adrenergic receptors
The decreased effectiveness of albuterol with frequent use is a phenomenon known as tachyphylaxis. This rapid decrease in drug response is primarily caused by pharmacodynamic tolerance, specifically the downregulation of β2-adrenergic receptors on bronchial smooth muscle cells. Continuous or repeated exposure to an agonist leads to phosphorylation, internalization, and degradation of the receptors, reducing the number available to bind the drug and mediate a response. Upregulation would increase sensitivity. Increased metabolism is a pharmacokinetic change. Antibody formation is a rare immunologic reaction.
- The intracellular signaling cascade initiated by insulin binding to its receptor primarily involves which of the following mechanisms?
Answer: Autophosphorylation of tyrosine residues
The insulin receptor is a receptor tyrosine kinase. It consists of two α-subunits and two β-subunits. When insulin binds to the extracellular α-subunits, it causes a conformational change that activates the tyrosine kinase domain located on the intracellular portion of the β-subunits. This activation leads to autophosphorylation of tyrosine residues on the receptor itself, which then creates docking sites for other signaling proteins (like IRS), initiating downstream pathways that mediate insulin's metabolic effects.
- The ability of buprenorphine to act as both a treatment and a potential precipitant of withdrawal is best explained by which of the following pharmacodynamic properties?
Answer: Partial agonist
Buprenorphine is a partial agonist at the μ-opioid receptor. This means it binds to the receptor and produces a submaximal response (lower efficacy than full agonists like morphine). This property provides relief from cravings and withdrawal without causing the same degree of euphoria and respiratory depression. However, because it has high affinity for the receptor, it can displace full agonists like morphine. When it displaces morphine, the overall receptor stimulation decreases, leading to a net reduction in effect and precipitating withdrawal symptoms.
- The need for close monitoring of this patient's medication is due to its narrow property of which of the following?
Answer: Therapeutic index
The therapeutic index (TI) is a measure of a drug's safety, calculated as the ratio of the toxic dose (TD50) to the effective dose (ED50). A narrow TI, as seen with lithium, indicates that the dose required for therapeutic effect is very close to the dose that causes toxicity. This small margin of safety necessitates regular monitoring of plasma drug concentrations to ensure they remain within the therapeutic range and to prevent adverse effects.
- Activation of which of the following downstream signaling pathways is primarily responsible for the vasoconstrictive effect of norepinephrine?
Answer: Activation of phospholipase C and increased intracellular calcium
α1-adrenergic receptors are G-protein coupled receptors that are linked to Gq proteins. Activation of the Gq protein stimulates phospholipase C (PLC). PLC then cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of calcium from the sarcoplasmic reticulum, and DAG activates protein kinase C. The resulting increase in intracellular calcium leads to smooth muscle contraction and vasoconstriction.
- Which of the following terms best describes Drug Z?
Answer: Inverse agonist
An inverse agonist binds to the same receptor as an agonist but elicits the opposite pharmacological response. In systems with constitutive (basal) activity, an inverse agonist reduces this activity below the baseline level. Drug X is an agonist, as it increases activity. Drug Y is a neutral antagonist, as it blocks the agonist but has no effect on its own. Drug Z is an inverse agonist because it reduces the receptor's activity below the constitutive level.
- The dose of 50 mg in this study represents which of the following pharmacodynamic parameters?
Answer: ED50 (Median effective dose)
The median effective dose (ED50) is the dose at which 50% of individuals in a population exhibit a specified quantal (all-or-none) effect. In this trial, the specified effect is achieving a target HbA1c < 7.0%. Since 250 out of 500 patients (50%) achieved this effect at a dose of 50 mg, this dose represents the ED50. LD50 and TD50 refer to lethal and toxic doses, respectively. Emax refers to the maximal response, not a population-based dose.
- The need for an increased dose to achieve the same effect, known as tolerance, is most likely due to which pharmacodynamic change at the GABAA receptor?
Answer: Changes in receptor conformation and coupling to chloride channels
Chronic use of benzodiazepines can lead to pharmacodynamic tolerance. This is thought to be caused by adaptive changes in the GABAA receptor itself. These changes include receptor downregulation (a decrease in the number of receptors) and, importantly, uncoupling of the benzodiazepine binding site from the GABA binding site and the chloride channel. This uncoupling means that even when the drug binds, it is less effective at potentiating the inhibitory effects of GABA, requiring a higher dose to achieve the same clinical effect.
- Based on these data, what is the therapeutic index for this drug, and what does it suggest about the drug's safety profile?
Answer: 10, suggesting a high margin of safety.
The therapeutic index (TI) is calculated as TD50 / ED50. In this case, TI = 200 mg/kg / 20 mg/kg = 10. A higher therapeutic index indicates a wider margin between the dose that produces a therapeutic effect and the dose that causes toxicity. Therefore, a TI of 10 suggests a relatively high (or wide) margin of safety, meaning that an overdose is less likely to occur with standard dosing adjustments compared to a drug with a TI of 2.
- The binding of albuterol to its receptor leads to smooth muscle relaxation through the increased intracellular concentration of which of the following second messengers?
Answer: Cyclic adenosine monophosphate (cAMP)
β2-adrenergic receptors are G-protein coupled receptors linked to Gs proteins. When an agonist like albuterol binds, the Gs protein activates adenylyl cyclase. Adenylyl cyclase then converts ATP to cyclic adenosine monophosphate (cAMP). Increased levels of cAMP in bronchial smooth muscle cells activate protein kinase A, which leads to phosphorylation of various proteins, resulting in decreased intracellular calcium and smooth muscle relaxation (bronchodilation).
- How would this exposure affect the dose-response relationship for acetylcholine at muscarinic receptors?
Answer: Shift the curve to the left, increasing potency
Organophosphates are acetylcholinesterase inhibitors. By inhibiting the enzyme that breaks down acetylcholine (ACh), they increase the concentration and duration of action of ACh in the synaptic cleft. This effectively increases the amount of agonist available to bind to muscarinic and nicotinic receptors for any given level of neuronal release. An increased agonist concentration produces a greater effect at a lower stimulus level, which is represented by a leftward shift in the dose-response curve, indicating an increase in the apparent potency of acetylcholine.
- Which of the following terms best describes Drug B?
Answer: Noncompetitive antagonist
A noncompetitive antagonist reduces the maximal effect (efficacy) of an agonist. This occurs because the antagonist binds to the receptor at a site different from the agonist (allosteric site) or binds irreversibly to the active site, effectively removing functional receptors from the system. Because this antagonism cannot be overcome by increasing the agonist concentration, the Emax is lowered. This is in contrast to a competitive antagonist, which would shift the dose-response curve to the right but not lower the Emax.
